X0202 SCHEDULE 13D/A 0001841619 XXXXXXXX LIVE 5 Common Stock 08/25/2026 false 0001787740 888705308 Valion Bio, Inc.

1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205

Maier J. Tarlow (646) 845-0040 2 Wooster Street, 2nd Floor New York NY 10013 0001841619 N 3i, LP a WC N DE 0.00 3334139.00 0.00 3334139.00 3334139.00 N 9.9 PN As more fully described in Item 5 of this Amendment No. 5 (as defined in Item 1 below), such shares and percentage are based on 32,140,634 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 2,100,000 shares of Common Stock directly held by 3i, LP and 1,234,139 shares of Common Stock issuable in any combination upon (i) exercises of certain common stock purchase warrants (the "Warrants") held directly by 3i, LP, which exercises are subject to a 9.99% beneficial ownership limitation provision (a "Blocker"), (ii) conversions of a senior secured convertible note in the original principal amount of $16,253,147.10 (the "Note") held directly by 3i, LP, which conversions are subject to a Blocker, (iii) conversions of shares of Series B Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series B Preferred Stock") directly held by 3i, LP, which conversions are subject to a Blocker, and (iv) conversions of shares of Series C Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series C Preferred Stock") directly held by the 3i, LP, which conversions are subject to a Blocker. Y Tumim Stone Capital, LLC a WC N DE 0.00 0.00 0.00 0.00 0.00 N 0.00 OO Y 3i Management LLC a WC N DE 0.00 3334139.00 0.00 3334139.00 3334139.00 N 9.9 OO As more fully described in Item 5 of this Amendment No. 5, such shares and percentage are based on 32,140,634 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 2,100,000 shares of Common Stock indirectly held by the reporting person and 1,234,139 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Y Maier J. Tarlow a WC N X1 0.00 3334139.00 0.00 3334139.00 3334139.00 N 9.9 IN As more fully described in Item 5 of this Amendment No. 5, such shares and percentage are based on 32,140,634 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 2,100,000 shares of Common Stock indirectly held by the reporting person and 1,234,139 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker. Common Stock Valion Bio, Inc. 1305 E. Houston Street, Building 1 Suite 311 San Antonio TX 78205 This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") relates to the common stock, par value $0.0001 per share (the "Common Stock") of Valion Bio, Inc., a Delaware corporation (the "Issuer"), and amends the Schedule 13D filed on August 3, 2026, as amended by Amendment No. 1 filed on August 11, 2026, Amendment No. 2 filed on August 14, 2026, Amendment No. 3 filed on August 19, 2026 and Amendment No. 4 filed on August 24, 2026 (as amended, the "Original Schedule 13D") by (a) 3i, LP, (b) Tumim Stone Capital, LLC ("Tumim Stone"), (c) 3i Management LLC ("3i Management") and (d) Maier J. Tarlow ("Mr. Tarlow" and, together with 3i, LP, 3i Management and Tumim Stone, the "Reporting Persons") as set forth herein. This Item 2(a) is not being amended by this Amendment No. 5. This Item 2(b) is not being amended by this Amendment No. 5. This Item 2(c) is not being amended by this Amendment No. 5. This Item 2(d) is not being amended by this Amendment No. 5. This Item 2(e) is not being amended by this Amendment No. 5. This Item 2(f) is not being amended by this Amendment No. 5. This Item 3 is not being amended by this Amendment No. 5. This Item 4 is not being amended by this Amendment No. 5. Item 5(a) of the Original Schedule 13D is hereby amended and restated as follows: See rows (11) and (13) of the cover pages to this statement for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons. The shares and percentages are based on 32,140,634 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. This Item 5(b) is not being amended by this Amendment No. 5. This Item 5(c) is hereby amended to add the transactions set forth in Exhibit 9 attached herein. This Item 5(d) is not being amended by this Amendment No. 5. This Item 5(e) is not being amended by this Amendment No. 5. This Item 6 is not being amended by this Amendment No. 5. Item 7 of the Original Schedule 13D is hereby amended to add the following exhibit: Exhibit 9: Additional Transactions 3i, LP /s/ Maier J. Tarlow 08/27/2026 Tumim Stone Capital, LLC /s/ Maier J. Tarlow 08/27/2026 3i Management LLC /s/ Maier J. Tarlow 08/27/2026 Maier J. Tarlow /s/ Maier J. Tarlow 08/27/2026